Managed Healthcare Executive June 23, 2025
The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded semaglutide products. Novo Nordisk said that Hims & Hers continues to offer these compounded drugs.
Novo Nordisk will no longer be working with Hims & Hers Health, and direct access to Wegovy (semaglutide) will no longer be available. In a news release, Novo Nordisk said the collaboration ended because Hims & Hers continues to offer compounded products for obesity.
Related: Novo Nordisk Offers Wegovy Through Telehealth Providers, Including Hims & Hers
In April 2025, Novo Nordisk teamed up with several telehealth providers, including Hims & Hers, to offer access to Wegovy injection 2.4 mg through CenterWell Pharmacy, which is the dispensing...
Today's Sponsors
Today's Sponsor